MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Other Events
Item 8.01 Other Events.
On January23, 2017, Marinus Pharmaceuticals,Inc. issued a press
release announcing preliminary data from the initial CDKL5
children enrolled in its ongoing Phase 2 open-label study
evaluating ganaxolone as a treatment for orphan, genetic
disorders. A copy of the press release is filed as Exhibit99.1 to
this Current Report on Form8-K, and the text of the press release
is incorporated by reference as though fully set forth herein.
Item 9.01 Financial Statements and Exhibits.
|
(d) |
Exhibits |
|
Exhibit No. |
|
Description |
|
99.1 |
Press Release, dated January23, 2017, of Marinus |
About MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS) Recent Trading Information
MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS) closed its last trading session down -0.05 at 1.26 with 2,976,232 shares trading hands.
